With 2 pioneering PD-1s lording it over the 6 approved checkpoints in its class, what difference can 1 more make?
The executive team at BeiGene is glad you asked.
On Monday, the Chinese biotech posted some remarkable results for their pivotal study aimed at gaining a quick OK in China for their PD-1 tislelizumab in treatment-resistant classical Hodgkin’s lymphoma. And they’re taking their best shot at making a case in San Diego that this one could be significantly better than its many rivals.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.Free Subscription